BR112014004890A8 - Bactéria, composição farmacêutica, alimentícia ou de ração, e, uso da bactéria - Google Patents

Bactéria, composição farmacêutica, alimentícia ou de ração, e, uso da bactéria

Info

Publication number
BR112014004890A8
BR112014004890A8 BR112014004890A BR112014004890A BR112014004890A8 BR 112014004890 A8 BR112014004890 A8 BR 112014004890A8 BR 112014004890 A BR112014004890 A BR 112014004890A BR 112014004890 A BR112014004890 A BR 112014004890A BR 112014004890 A8 BR112014004890 A8 BR 112014004890A8
Authority
BR
Brazil
Prior art keywords
bacteria
insulin resistance
rel
diabetes mellitus
type
Prior art date
Application number
BR112014004890A
Other languages
English (en)
Other versions
BR112014004890A2 (pt
Inventor
Nieuwdorp Max
Meidert De Vos Willen
Original Assignee
Acad Medisch Ct
Univ Wageningen
Caelus Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47756609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014004890(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acad Medisch Ct, Univ Wageningen, Caelus Pharmaceuticals B V filed Critical Acad Medisch Ct
Publication of BR112014004890A2 publication Critical patent/BR112014004890A2/pt
Publication of BR112014004890A8 publication Critical patent/BR112014004890A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells

Abstract

BACTÉRIA, COMPOSIÇÃO FARMACÊUTICA, ALIMENTÍCIA OU DE RAÇÃO, E, USO DA BACTÉRIA. A presente invenção descreve o uso de Eubacterium hallii et rel. e/ou Alcaligenes faecalis et rel., assim como composições farmacêuticas, alimentícias, ou ração que compreendem essas bactérias, como um medicamento, em particular para prevenir e/ou tratar a resistência à insulina e/ou complicações relacionadas com a resistência à insulina tais como síndrome metabólica, dislipidemia e diabete mellitus tipo 2 assim como resistência à insulina em doenças endócrinas (por exemplo, indivíduos obesos com diabete mellitus tipo 1, doença de Cushing e síndrome de lipodistrofia. Também é descrito um método para prevenir e/ou tratar a resistência à insulina e/ou complicações relacionadas com a resistência à insulina tais como dislipidemia e diabete mellitus tipo 2 assim como a resistência à insulina em doenças endócrinas (por exemplo, indivíduos obesos com diabete mellitus tipo 1, doença de Cushing e síndrome de lipodistrofia) em um indivíduo em necessidade do mesmo, o dito método compreendendo a etapa de aumentar o nível de Eubacterium hallii et rel. e/ou Alcaligenes faecalis et rel. no intestino delgado.
BR112014004890A 2011-08-30 2012-08-30 Bactéria, composição farmacêutica, alimentícia ou de ração, e, uso da bactéria BR112014004890A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161528931P 2011-08-30 2011-08-30
NL2007319 2011-08-30
PCT/NL2012/050592 WO2013032328A1 (en) 2011-08-30 2012-08-30 Method for preventing and/or treating insulin resistance

Publications (2)

Publication Number Publication Date
BR112014004890A2 BR112014004890A2 (pt) 2017-03-21
BR112014004890A8 true BR112014004890A8 (pt) 2018-02-06

Family

ID=47756609

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004890A BR112014004890A8 (pt) 2011-08-30 2012-08-30 Bactéria, composição farmacêutica, alimentícia ou de ração, e, uso da bactéria

Country Status (13)

Country Link
US (2) US9433650B2 (pt)
EP (1) EP2753187B1 (pt)
JP (1) JP6116568B2 (pt)
KR (1) KR101982491B1 (pt)
CN (1) CN104244733B (pt)
AU (1) AU2012302364B2 (pt)
BR (1) BR112014004890A8 (pt)
CA (1) CA2851602C (pt)
DK (1) DK2753187T3 (pt)
PL (1) PL2753187T3 (pt)
RU (1) RU2613322C2 (pt)
SG (1) SG11201401811WA (pt)
WO (1) WO2013032328A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6116568B2 (ja) 2011-08-30 2017-04-19 アカデミッシュ メディッシュ セントラム インスリン抵抗性を予防および／または処置する方法
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3904502A3 (en) 2013-02-04 2022-02-23 Seres Therapeutics, Inc. Compositions and methods
CN110917220A (zh) 2013-02-04 2020-03-27 赛里斯治疗公司 治疗组合物及其使用方法
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
JP6637885B2 (ja) 2013-07-21 2020-01-29 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
RU2722482C2 (ru) 2013-11-25 2020-06-01 Серес Терапеутикс, Инк. Синергические бактериальные композиции и способы их получения и применения
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6868562B2 (ja) 2014-10-31 2021-05-19 ペンデュラム セラピューティクス， インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
KR20170103920A (ko) 2015-01-09 2017-09-13 바게닝겐 유니버시테이트 위장관, 대사성 및/또는 기타 질환의 치료 및/또는 예방을 위한 박테리아-함유 조성물 및 이의 사용 방법
BR112018013292A2 (pt) 2015-12-31 2018-12-04 Caelus Pharmaceuticals B V ?método para preparar uma preparação de e. hallii e para promover formação de ácido butírico, e, preparação de e. hallii?
CN106974939B (zh) * 2016-01-15 2020-08-25 深圳华大生命科学研究院 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
US10799558B2 (en) 2016-02-02 2020-10-13 Oncoimmune, Inc. Use of CD24 proteins for treating leptin-deficient conditions
RU2730870C2 (ru) 2016-02-25 2020-08-26 Калус Фармасьютикалс Б.В. Композиции и способы для профилактики и/или лечения недостатка витамина в12
JP7012377B2 (ja) 2016-04-11 2022-02-14 ヴァーヘニンゲン ユニバーシテイト 新規な細菌種
US10729670B2 (en) 2016-09-07 2020-08-04 Temple University—Of The Commonwealth Systems Of Higher Education Compositions and methods for treatment of insulin resistance
EP3570855A1 (en) * 2017-01-19 2019-11-27 Pleonova AB Autologous fecal sample for use in the treatment of microbial dysbiosis
CN111212655A (zh) 2017-08-14 2020-05-29 赛里斯治疗公司 用于治疗胆汁淤积性疾病的组合物和方法
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
AU2019229090A1 (en) * 2018-03-02 2020-10-08 Academisch Medisch Centrum Fecal matter for prevention or treatment of autoimmune diseases
WO2020018949A2 (en) * 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
US20220228105A1 (en) 2019-08-14 2022-07-21 Wageningen Universiteit Bacterium comprising myo-inositol to propionate pathway
NL2024569B1 (en) 2019-12-24 2021-09-06 Univ Wageningen Bacterium comprising myo-inositol to propionate pathway
RU2734336C1 (ru) * 2020-03-27 2020-10-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ ранней неинвазивной диагностики метаболических нарушений у детей и подростков
EP4228665A1 (en) * 2020-10-14 2023-08-23 Dermbiont, Inc. Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with fungi and other pathogenic microbes
CN113604400B (zh) * 2021-08-26 2023-06-02 王玉莹 具有预防或治疗糖尿病作用的新型乳杆菌yuyingw

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
ATE296109T1 (de) * 1996-03-20 2005-06-15 Baxter Ag Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US6227863B1 (en) 1998-02-18 2001-05-08 Donald Spector Phonics training computer system for teaching spelling and reading
US6224863B1 (en) * 1998-10-30 2001-05-01 University Of South Carolina Antibiotic composition from alcaligenes species and method for making and using the same
EP1228769A1 (de) * 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiontisches Regenerativum
JP4307006B2 (ja) * 2002-03-28 2009-08-05 キリンフードテック株式会社 糖尿病予防剤
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
US20080069861A1 (en) * 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
JP5350626B2 (ja) 2007-12-20 2013-11-27 キリンフードテック株式会社 樹状細胞活性化用組成物
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
ES2666331T3 (es) * 2009-01-23 2018-05-04 Kadant Inc. Sistema para suministrar desempeño de desaguado mejorado en una máquina para fabricar papel
CA2776420A1 (en) * 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
JP5778669B2 (ja) * 2010-05-18 2015-09-16 エイブル株式会社 メタン生成の抑制方法
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
JP6116568B2 (ja) 2011-08-30 2017-04-19 アカデミッシュ メディッシュ セントラム インスリン抵抗性を予防および／または処置する方法

Also Published As

Publication number Publication date
DK2753187T3 (en) 2019-01-28
WO2013032328A1 (en) 2013-03-07
CN104244733A (zh) 2014-12-24
CN104244733B (zh) 2017-07-28
US9623055B2 (en) 2017-04-18
US9433650B2 (en) 2016-09-06
KR20140128936A (ko) 2014-11-06
CA2851602A1 (en) 2013-03-07
KR101982491B1 (ko) 2019-05-27
JP2014527068A (ja) 2014-10-09
AU2012302364B2 (en) 2016-07-28
PL2753187T3 (pl) 2019-05-31
EP2753187B1 (en) 2018-10-24
EP2753187A1 (en) 2014-07-16
US20160317589A1 (en) 2016-11-03
RU2613322C2 (ru) 2017-03-15
CA2851602C (en) 2020-07-14
AU2012302364A1 (en) 2014-04-17
JP6116568B2 (ja) 2017-04-19
RU2014112223A (ru) 2015-10-10
BR112014004890A2 (pt) 2017-03-21
US20140294774A1 (en) 2014-10-02
SG11201401811WA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
BR112014004890A8 (pt) Bactéria, composição farmacêutica, alimentícia ou de ração, e, uso da bactéria
CO6781465A2 (es) Composición farmacéutica, métodos de tratamiento y usos de la misma
CU20130073A7 (es) Péptidos derivados del factor de crecimiento de fibroblastos 21 ( fgf21) útiles como reguladores metabólicos
CL2014000801A1 (es) Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
BR112013018782A2 (pt) compostos e seus efeitos no comportamento alimentar
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
CL2013002414A1 (es) Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
CL2008001612A1 (es) 5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
BRPI0718596B8 (pt) composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina
BR112012018703A2 (pt) compostos e seus efeitos sobre o comportamento alimentar
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
BR112015004734A2 (pt) proteínas de fusão para tratar uma síndrome metabólica
CL2013002210A1 (es) Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano.
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
BR112017017538A2 (pt) maltooligossacarídeos ricos em fibra que têm biodisponibilidade de glicose baixa, método de fabricação dos mesmos e uso dos mesmos em alimento humano e alimentação animal
BR112012001912A8 (pt) Composições nutritivas que compreendem fibra e probióticos
BR112012005044B8 (pt) composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib
UY31873A (es) Pirrolidin sulfonamidas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas
BR112019004534A2 (pt) análogo de amilina, método para a síntese e composição farmacêutica
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
BR112013029062A2 (pt) lixisenatida e metformina para o tratamento de diabetes tipo 2
BRPI0822069B8 (pt) método para preparação de um extrato de fruta de cardo leiteiro

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ACADEMISCH MEDISCH CENTRUM (NL) , CAELUS PHARMACEU

B15K Others concerning applications: alteration of classification

Ipc: A61K 35/74 (2015.01), A23K 10/16 (2016.01), A23L 2

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL